A phase II trial was conducted to determine the efficacy and toxicity of the addition of
interferon-[alpha] 2b (IFN-a [alpha]) to the chemotherapy combination of dacarbazine …

The therapeutic benefit of adding interferon α (IFNα) to established single-agent and
combination chemotherapy regimens for the treatment of metastatic melanoma has not been …

Abstract Treatment of patients with metastatic melanoma with either dacarbazine (DTIC) or
interferon-α (IFNα) as single drugs, or in combination, results in a response rate of …

PURPOSE Some phase II studies have suggested that the combination of interferons (IFNs)
with dacarbazine (DTIC) in the treatment of malignant melanoma (MM) increases the …

52 patients with metastatic melanoma have been treated with a combination of recombinant
interferon-alfa-2b, dacarbazine and nimustine. The objective response rate was 23% with 9 …

A prospectively randomized trial was undertaken to compare dacarbazine (DTIC) alone with
DTIC plus interferon in patients with metastatic malignant melanoma. Of the 73 patients who …

PURPOSE The goal of this study was to determine the therapeutic efficacy and toxicity of a
four-drug chemotherapy regimen combined with natural leukocyte interferon alfa (IFN-alpha) …

Following extensive phase II trials of the combination of dacarbazine and interferon-alpha
2a we performed a prospective, randomized, controlled trial of this combination versus …

Since cytotoxic chemotherapy (BCNU, DTIC and cisplatin, tamoxifen) and interferon-
[alpha](IFN-[alpha]) have each produced responses in advanced malignant melanoma, a …

PURPOSE To investigate the response rate, time to treatment failure (TTF), overall survival,
and toxicity in patients with metastatic melanoma treated with dacarbazine alone …